Biochemical Engineering

Alchemab Therapeutics signs $415m licensing agreement for ATLX-1282 with Eli Lilly

Alchemab Therapeutics signs $415m licensing agreement for ATLX-1282 with Eli Lilly

6th May 2025

Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415m. Source: Alchemab press release 6/5/2025


Back to group news